| Variables . | Total (n = 42) . | ICU (n = 28) . | Medical department (n = 14) . | P-valuea . |
|---|---|---|---|---|
| Consumption of NSAID drugs before hospitalization, n (%) | 2 (5)b | 1 (4)b | 1 (7) | 1 |
| Symptoms at admission, n (%) | ||||
| Fever | 35 (83) | 22 (79) | 13 (93) | 0.39 |
| Cough | 31 (74) | 20 (71) | 11 (79) | 0.72 |
| Diarrhoea | 13 (31) | 10 (36) | 3 (21) | 0.49 |
| Myalgia | 11 (26) | 5 (18) | 6 (43) | 0.14 |
| Headache | 7 (17) | 3 (11) | 4 (29) | 0.20 |
| Anosmia | 4 (10) | 0 (0) | 4 (29) | 0.0089 |
| Aguesia | 4 (10) | 0 (0) | 4 (29) | 0.0089 |
| Dyspnoea | 36 (86) | 25 (89) | 11 (79) | 0.38 |
| Clinical respiratory distress | 24 (57) | 20 (71) | 4 (29) | 0.019 |
| Confusion | 2 (5) | 2 (7) | 0 (0) | 0.54 |
| Severity score in intensive care | ||||
| SAPS-II score at admission | 38.5 (28.5–47.3)c | 38.5 (28.5–47.3)c | – | – |
| SOFA score at Day 1 | 3.5 (3.0–6.8)c | 3.5 (3.0–6.8)c | – | – |
| SOFA score at the day of first renal function assessment | 4.0 (3.0–6.0)c | 4.0 (3.0–6.0)c | – | – |
| Pulmonary disease | ||||
| Typical radiological pulmonary involvement | 38 (95)d | 25 (96)d | 13 (92) | 1 |
| Chest scanner | 25 (63)d | 13 (50)d | 12 (86) | 0.04 |
| Chest X-ray | 19 (48)d | 15 (58)d | 4 (29) | 0.10 |
| Initial arterial blood gases | ||||
| Ph | 7.45 (7.39–7.47)e | 7.43 (7.36–7.47) | 7.45 (7.43–7.47)e | 0.17 |
| pCO2, mmHg | 33.7 (31.0–39.0)e | 33.9 (30.7–45.2) | 33.7 (33.1–35.3)e | 0.78 |
| PaO2/FiO2, mmHg | 221 (111–277)f | 196 (103–265)f | 296 (223–322)f | 0.0065 |
| Pulmonary diagnosis (%) | ||||
| Initial PaO2/FiO2 >300 mmHg | 7 (18)f | 1 (4)f | 6 (46)f | 0.0009 |
| Acute lung injury | 17 (44)f | 12 (44)f | 5 (42)f | |
| ARDS | 15 (38)f | 14 (52)f | 1 (8)f | |
| Pulmonary treatment, n (%) | ||||
| Mechanical ventilation | 26 (62) | 26 (93) | 0 (0) | <0.0001 |
| Prone positioning | 23 (55) | 23 (82) | 0 (0) | <0.0001 |
| Cardiac and haemodynamic disorders, n (%) | ||||
| Myocarditis | 1 (2) | 1 (4) | 0 (0) | 1 |
| High-sensitive cardiac troponin I (expressed in pg/mL) | 17.1 (8.0–52.0)g | 17.5 (12.0–68.3)g | 17.1 (2.0–41.0)g | 0.36 |
| High-sensitive cardiac troponin I >24 pg/mL | 12 (34)g | 9 (35)g | 3 (43)g | 0.69 |
| Electrocardiogram analyses | ||||
| Repolarization abnormalities | 1 (3)h | 1 (4)h | 0 (0)h | 1 |
| Supraventricular rhythm disorder | 4 (10)h | 3 (12)h | 1 (8)h | 1 |
| Haemodynamic failure (noradrenaline treatment) | 14 (33) | 14 (50) | 0 | 0.0012 |
| Acute hepatitis, n (%) | 29 (69) | 23 (82) | 6 (43) | 0.015 |
| SGPT | 66.5 (33.5–117.5) | 77.5 (52.8–154.5) | 29.0 (19.0–85.0) | 0.002 |
| SGOT | 72.5 (38.0–115.8) | 95.0 (47.8–135.3) | 40.5 (24.8–67.3) | 0.0023 |
| COVID-19 and associated treatments, n (%) | ||||
| Lopinavir + ritonavir (Kaletra®) | 11 (28)e | 10 (36) | 1 (8)e | 0.12 |
| Remdesivir | 1 (3)e | 1 (4) | 0 (0)e | 10.0190.210.006 |
| Initial oseltamivir (Tamiflu®) | 10 (25)e | 10 (36) | 0 (0)e | |
| Antibiotics | 37 (93)e | 27 (96) | 10 (83)e | |
| Third-generation cephalosporin | 34 (85)e | 27 (96) | 7 (58)e | |
| Rovamycin or azithromycin | 19 (48)e | 17 (61) | 2 (17)e | 0.013 |
| Amoxicillin + clavulanic acid | 2 (5)e | 1 (4) | 1 (8)e | 1 |
| Aminoglycosides | 2 (5)e | 1 (4) | 1 (8)e | 1 |
| Variables . | Total (n = 42) . | ICU (n = 28) . | Medical department (n = 14) . | P-valuea . |
|---|---|---|---|---|
| Consumption of NSAID drugs before hospitalization, n (%) | 2 (5)b | 1 (4)b | 1 (7) | 1 |
| Symptoms at admission, n (%) | ||||
| Fever | 35 (83) | 22 (79) | 13 (93) | 0.39 |
| Cough | 31 (74) | 20 (71) | 11 (79) | 0.72 |
| Diarrhoea | 13 (31) | 10 (36) | 3 (21) | 0.49 |
| Myalgia | 11 (26) | 5 (18) | 6 (43) | 0.14 |
| Headache | 7 (17) | 3 (11) | 4 (29) | 0.20 |
| Anosmia | 4 (10) | 0 (0) | 4 (29) | 0.0089 |
| Aguesia | 4 (10) | 0 (0) | 4 (29) | 0.0089 |
| Dyspnoea | 36 (86) | 25 (89) | 11 (79) | 0.38 |
| Clinical respiratory distress | 24 (57) | 20 (71) | 4 (29) | 0.019 |
| Confusion | 2 (5) | 2 (7) | 0 (0) | 0.54 |
| Severity score in intensive care | ||||
| SAPS-II score at admission | 38.5 (28.5–47.3)c | 38.5 (28.5–47.3)c | – | – |
| SOFA score at Day 1 | 3.5 (3.0–6.8)c | 3.5 (3.0–6.8)c | – | – |
| SOFA score at the day of first renal function assessment | 4.0 (3.0–6.0)c | 4.0 (3.0–6.0)c | – | – |
| Pulmonary disease | ||||
| Typical radiological pulmonary involvement | 38 (95)d | 25 (96)d | 13 (92) | 1 |
| Chest scanner | 25 (63)d | 13 (50)d | 12 (86) | 0.04 |
| Chest X-ray | 19 (48)d | 15 (58)d | 4 (29) | 0.10 |
| Initial arterial blood gases | ||||
| Ph | 7.45 (7.39–7.47)e | 7.43 (7.36–7.47) | 7.45 (7.43–7.47)e | 0.17 |
| pCO2, mmHg | 33.7 (31.0–39.0)e | 33.9 (30.7–45.2) | 33.7 (33.1–35.3)e | 0.78 |
| PaO2/FiO2, mmHg | 221 (111–277)f | 196 (103–265)f | 296 (223–322)f | 0.0065 |
| Pulmonary diagnosis (%) | ||||
| Initial PaO2/FiO2 >300 mmHg | 7 (18)f | 1 (4)f | 6 (46)f | 0.0009 |
| Acute lung injury | 17 (44)f | 12 (44)f | 5 (42)f | |
| ARDS | 15 (38)f | 14 (52)f | 1 (8)f | |
| Pulmonary treatment, n (%) | ||||
| Mechanical ventilation | 26 (62) | 26 (93) | 0 (0) | <0.0001 |
| Prone positioning | 23 (55) | 23 (82) | 0 (0) | <0.0001 |
| Cardiac and haemodynamic disorders, n (%) | ||||
| Myocarditis | 1 (2) | 1 (4) | 0 (0) | 1 |
| High-sensitive cardiac troponin I (expressed in pg/mL) | 17.1 (8.0–52.0)g | 17.5 (12.0–68.3)g | 17.1 (2.0–41.0)g | 0.36 |
| High-sensitive cardiac troponin I >24 pg/mL | 12 (34)g | 9 (35)g | 3 (43)g | 0.69 |
| Electrocardiogram analyses | ||||
| Repolarization abnormalities | 1 (3)h | 1 (4)h | 0 (0)h | 1 |
| Supraventricular rhythm disorder | 4 (10)h | 3 (12)h | 1 (8)h | 1 |
| Haemodynamic failure (noradrenaline treatment) | 14 (33) | 14 (50) | 0 | 0.0012 |
| Acute hepatitis, n (%) | 29 (69) | 23 (82) | 6 (43) | 0.015 |
| SGPT | 66.5 (33.5–117.5) | 77.5 (52.8–154.5) | 29.0 (19.0–85.0) | 0.002 |
| SGOT | 72.5 (38.0–115.8) | 95.0 (47.8–135.3) | 40.5 (24.8–67.3) | 0.0023 |
| COVID-19 and associated treatments, n (%) | ||||
| Lopinavir + ritonavir (Kaletra®) | 11 (28)e | 10 (36) | 1 (8)e | 0.12 |
| Remdesivir | 1 (3)e | 1 (4) | 0 (0)e | 10.0190.210.006 |
| Initial oseltamivir (Tamiflu®) | 10 (25)e | 10 (36) | 0 (0)e | |
| Antibiotics | 37 (93)e | 27 (96) | 10 (83)e | |
| Third-generation cephalosporin | 34 (85)e | 27 (96) | 7 (58)e | |
| Rovamycin or azithromycin | 19 (48)e | 17 (61) | 2 (17)e | 0.013 |
| Amoxicillin + clavulanic acid | 2 (5)e | 1 (4) | 1 (8)e | 1 |
| Aminoglycosides | 2 (5)e | 1 (4) | 1 (8)e | 1 |
Data are expressed as median (range) or n (%) when appropriate.
Analysis of ICU versus Medical department.
Four missing data in ICU.
Six missing data in ICU.
Two missing data in ICU.
Two missing data in Medical department.
One missing data in ICU and two missing data in Medical department.
Two missing data in ICU and seven missing data in Medical department.
Two missing data in ICU and one missing data in Medical department.
NSAID: non-steroidal anti-inflammatory drugs.
Bold value: the p is <0.05
| Variables . | Total (n = 42) . | ICU (n = 28) . | Medical department (n = 14) . | P-valuea . |
|---|---|---|---|---|
| Consumption of NSAID drugs before hospitalization, n (%) | 2 (5)b | 1 (4)b | 1 (7) | 1 |
| Symptoms at admission, n (%) | ||||
| Fever | 35 (83) | 22 (79) | 13 (93) | 0.39 |
| Cough | 31 (74) | 20 (71) | 11 (79) | 0.72 |
| Diarrhoea | 13 (31) | 10 (36) | 3 (21) | 0.49 |
| Myalgia | 11 (26) | 5 (18) | 6 (43) | 0.14 |
| Headache | 7 (17) | 3 (11) | 4 (29) | 0.20 |
| Anosmia | 4 (10) | 0 (0) | 4 (29) | 0.0089 |
| Aguesia | 4 (10) | 0 (0) | 4 (29) | 0.0089 |
| Dyspnoea | 36 (86) | 25 (89) | 11 (79) | 0.38 |
| Clinical respiratory distress | 24 (57) | 20 (71) | 4 (29) | 0.019 |
| Confusion | 2 (5) | 2 (7) | 0 (0) | 0.54 |
| Severity score in intensive care | ||||
| SAPS-II score at admission | 38.5 (28.5–47.3)c | 38.5 (28.5–47.3)c | – | – |
| SOFA score at Day 1 | 3.5 (3.0–6.8)c | 3.5 (3.0–6.8)c | – | – |
| SOFA score at the day of first renal function assessment | 4.0 (3.0–6.0)c | 4.0 (3.0–6.0)c | – | – |
| Pulmonary disease | ||||
| Typical radiological pulmonary involvement | 38 (95)d | 25 (96)d | 13 (92) | 1 |
| Chest scanner | 25 (63)d | 13 (50)d | 12 (86) | 0.04 |
| Chest X-ray | 19 (48)d | 15 (58)d | 4 (29) | 0.10 |
| Initial arterial blood gases | ||||
| Ph | 7.45 (7.39–7.47)e | 7.43 (7.36–7.47) | 7.45 (7.43–7.47)e | 0.17 |
| pCO2, mmHg | 33.7 (31.0–39.0)e | 33.9 (30.7–45.2) | 33.7 (33.1–35.3)e | 0.78 |
| PaO2/FiO2, mmHg | 221 (111–277)f | 196 (103–265)f | 296 (223–322)f | 0.0065 |
| Pulmonary diagnosis (%) | ||||
| Initial PaO2/FiO2 >300 mmHg | 7 (18)f | 1 (4)f | 6 (46)f | 0.0009 |
| Acute lung injury | 17 (44)f | 12 (44)f | 5 (42)f | |
| ARDS | 15 (38)f | 14 (52)f | 1 (8)f | |
| Pulmonary treatment, n (%) | ||||
| Mechanical ventilation | 26 (62) | 26 (93) | 0 (0) | <0.0001 |
| Prone positioning | 23 (55) | 23 (82) | 0 (0) | <0.0001 |
| Cardiac and haemodynamic disorders, n (%) | ||||
| Myocarditis | 1 (2) | 1 (4) | 0 (0) | 1 |
| High-sensitive cardiac troponin I (expressed in pg/mL) | 17.1 (8.0–52.0)g | 17.5 (12.0–68.3)g | 17.1 (2.0–41.0)g | 0.36 |
| High-sensitive cardiac troponin I >24 pg/mL | 12 (34)g | 9 (35)g | 3 (43)g | 0.69 |
| Electrocardiogram analyses | ||||
| Repolarization abnormalities | 1 (3)h | 1 (4)h | 0 (0)h | 1 |
| Supraventricular rhythm disorder | 4 (10)h | 3 (12)h | 1 (8)h | 1 |
| Haemodynamic failure (noradrenaline treatment) | 14 (33) | 14 (50) | 0 | 0.0012 |
| Acute hepatitis, n (%) | 29 (69) | 23 (82) | 6 (43) | 0.015 |
| SGPT | 66.5 (33.5–117.5) | 77.5 (52.8–154.5) | 29.0 (19.0–85.0) | 0.002 |
| SGOT | 72.5 (38.0–115.8) | 95.0 (47.8–135.3) | 40.5 (24.8–67.3) | 0.0023 |
| COVID-19 and associated treatments, n (%) | ||||
| Lopinavir + ritonavir (Kaletra®) | 11 (28)e | 10 (36) | 1 (8)e | 0.12 |
| Remdesivir | 1 (3)e | 1 (4) | 0 (0)e | 10.0190.210.006 |
| Initial oseltamivir (Tamiflu®) | 10 (25)e | 10 (36) | 0 (0)e | |
| Antibiotics | 37 (93)e | 27 (96) | 10 (83)e | |
| Third-generation cephalosporin | 34 (85)e | 27 (96) | 7 (58)e | |
| Rovamycin or azithromycin | 19 (48)e | 17 (61) | 2 (17)e | 0.013 |
| Amoxicillin + clavulanic acid | 2 (5)e | 1 (4) | 1 (8)e | 1 |
| Aminoglycosides | 2 (5)e | 1 (4) | 1 (8)e | 1 |
| Variables . | Total (n = 42) . | ICU (n = 28) . | Medical department (n = 14) . | P-valuea . |
|---|---|---|---|---|
| Consumption of NSAID drugs before hospitalization, n (%) | 2 (5)b | 1 (4)b | 1 (7) | 1 |
| Symptoms at admission, n (%) | ||||
| Fever | 35 (83) | 22 (79) | 13 (93) | 0.39 |
| Cough | 31 (74) | 20 (71) | 11 (79) | 0.72 |
| Diarrhoea | 13 (31) | 10 (36) | 3 (21) | 0.49 |
| Myalgia | 11 (26) | 5 (18) | 6 (43) | 0.14 |
| Headache | 7 (17) | 3 (11) | 4 (29) | 0.20 |
| Anosmia | 4 (10) | 0 (0) | 4 (29) | 0.0089 |
| Aguesia | 4 (10) | 0 (0) | 4 (29) | 0.0089 |
| Dyspnoea | 36 (86) | 25 (89) | 11 (79) | 0.38 |
| Clinical respiratory distress | 24 (57) | 20 (71) | 4 (29) | 0.019 |
| Confusion | 2 (5) | 2 (7) | 0 (0) | 0.54 |
| Severity score in intensive care | ||||
| SAPS-II score at admission | 38.5 (28.5–47.3)c | 38.5 (28.5–47.3)c | – | – |
| SOFA score at Day 1 | 3.5 (3.0–6.8)c | 3.5 (3.0–6.8)c | – | – |
| SOFA score at the day of first renal function assessment | 4.0 (3.0–6.0)c | 4.0 (3.0–6.0)c | – | – |
| Pulmonary disease | ||||
| Typical radiological pulmonary involvement | 38 (95)d | 25 (96)d | 13 (92) | 1 |
| Chest scanner | 25 (63)d | 13 (50)d | 12 (86) | 0.04 |
| Chest X-ray | 19 (48)d | 15 (58)d | 4 (29) | 0.10 |
| Initial arterial blood gases | ||||
| Ph | 7.45 (7.39–7.47)e | 7.43 (7.36–7.47) | 7.45 (7.43–7.47)e | 0.17 |
| pCO2, mmHg | 33.7 (31.0–39.0)e | 33.9 (30.7–45.2) | 33.7 (33.1–35.3)e | 0.78 |
| PaO2/FiO2, mmHg | 221 (111–277)f | 196 (103–265)f | 296 (223–322)f | 0.0065 |
| Pulmonary diagnosis (%) | ||||
| Initial PaO2/FiO2 >300 mmHg | 7 (18)f | 1 (4)f | 6 (46)f | 0.0009 |
| Acute lung injury | 17 (44)f | 12 (44)f | 5 (42)f | |
| ARDS | 15 (38)f | 14 (52)f | 1 (8)f | |
| Pulmonary treatment, n (%) | ||||
| Mechanical ventilation | 26 (62) | 26 (93) | 0 (0) | <0.0001 |
| Prone positioning | 23 (55) | 23 (82) | 0 (0) | <0.0001 |
| Cardiac and haemodynamic disorders, n (%) | ||||
| Myocarditis | 1 (2) | 1 (4) | 0 (0) | 1 |
| High-sensitive cardiac troponin I (expressed in pg/mL) | 17.1 (8.0–52.0)g | 17.5 (12.0–68.3)g | 17.1 (2.0–41.0)g | 0.36 |
| High-sensitive cardiac troponin I >24 pg/mL | 12 (34)g | 9 (35)g | 3 (43)g | 0.69 |
| Electrocardiogram analyses | ||||
| Repolarization abnormalities | 1 (3)h | 1 (4)h | 0 (0)h | 1 |
| Supraventricular rhythm disorder | 4 (10)h | 3 (12)h | 1 (8)h | 1 |
| Haemodynamic failure (noradrenaline treatment) | 14 (33) | 14 (50) | 0 | 0.0012 |
| Acute hepatitis, n (%) | 29 (69) | 23 (82) | 6 (43) | 0.015 |
| SGPT | 66.5 (33.5–117.5) | 77.5 (52.8–154.5) | 29.0 (19.0–85.0) | 0.002 |
| SGOT | 72.5 (38.0–115.8) | 95.0 (47.8–135.3) | 40.5 (24.8–67.3) | 0.0023 |
| COVID-19 and associated treatments, n (%) | ||||
| Lopinavir + ritonavir (Kaletra®) | 11 (28)e | 10 (36) | 1 (8)e | 0.12 |
| Remdesivir | 1 (3)e | 1 (4) | 0 (0)e | 10.0190.210.006 |
| Initial oseltamivir (Tamiflu®) | 10 (25)e | 10 (36) | 0 (0)e | |
| Antibiotics | 37 (93)e | 27 (96) | 10 (83)e | |
| Third-generation cephalosporin | 34 (85)e | 27 (96) | 7 (58)e | |
| Rovamycin or azithromycin | 19 (48)e | 17 (61) | 2 (17)e | 0.013 |
| Amoxicillin + clavulanic acid | 2 (5)e | 1 (4) | 1 (8)e | 1 |
| Aminoglycosides | 2 (5)e | 1 (4) | 1 (8)e | 1 |
Data are expressed as median (range) or n (%) when appropriate.
Analysis of ICU versus Medical department.
Four missing data in ICU.
Six missing data in ICU.
Two missing data in ICU.
Two missing data in Medical department.
One missing data in ICU and two missing data in Medical department.
Two missing data in ICU and seven missing data in Medical department.
Two missing data in ICU and one missing data in Medical department.
NSAID: non-steroidal anti-inflammatory drugs.
Bold value: the p is <0.05
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
